Implantable members for receiving therapeutically useful compositions

• US 6,129,757 A
• Filed: 05/18/1998
• Issued: 10/10/2000
• Est. Priority Date: 05/18/1998
• Status: Expired due to Term

• Current Assignee: Boston Scientific Scimed (Boston Scientific Corporation)
• Original Assignee: Scimed Life Systems Incorporated (Boston Scientific Corporation)
• Inventors: Weadock, Kevin
• Primary Examiner(s): Yu, Mickey
• Assistant Examiner(s): Koh, Choon P.
• Application Number:
  US09/080,736
• Time in Patent Office: 876 Days
• Field of Search: 623/11, 623/12, 623/1, 623/16, 623/18, 623/901, 623/1.39, 623/1.42, 623/1.49
• US Class Current: 623/1.39
• CPC Class Codes: A61L 2300/104 Silver, e.g. silver sulfadiazine
• CPC Class Codes: A61L 2300/404 Biocides, antimicrobial agents, antiseptic agents
• CPC Class Codes: A61L 2300/406 Antibiotics
• CPC Class Codes: A61L 2300/408 Virucides, spermicides
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/42 Anti-thrombotic agents, anticoagulants, anti-platelet agents
• CPC Class Codes: A61L 2300/44 Radioisotopes, radionuclides
• CPC Class Codes: A61L 2300/64 Animal cells
• CPC Class Codes: A61L 27/38 containing added animal cells organs or tissue containing native cells A61L27/36
• CPC Class Codes: A61L 27/3808 Endothelial cells
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 27/56 Porous materials, e.g. foams or sponges
• CPC Class Codes: Y10S 623/901 Method of manufacturing prosthetic device

Abstract

An implantable prosthesis includes a porous polymeric member having pores present in its wall structure wherein these pores contain a variety of therapeutically useful compositions including, collagen, genetically altered cells and piezoelectric materials. A process of preparing such a prosthesis is also disclosed.

Claims

1. An implantable member comprising a porous polymeric substrate having a wall structure substantially free of ePTFE nodes and fibrils structure, said wall structure having pores filled with a fluid composition that contains one or more substances which are precipitated out in situ to form an insoluble, biocompatible, biodegradable material therein.

2. The implantable member of claim 1, wherein said substances are selected from the group consisting of thrombo-resistant agents, antibiotic agents, anti-tumor agents, growth hormones, antiviral agents, anti-angiogenic agents, angiogenic agents, anti-mitotic agents, anti-inflammatory agents, cell cycle regulating agents, genetic agents, hormones, their homologs, derivatives, fragments, pharmaceutical salts, and combinations thereof.

3. The implantable member of claim 2, wherein said thrombo-resistant agents are selected from the group consisting of heparin, heparin sulfate, hirudin, hyaluronic acid, chondroitin sulfate, dermatan sulfate, keratan sulfate, lytic agents, including urokinase and streptokinase their homologs, analogs, fragments, derivatives and pharmaceutical salts thereof.

4. The implantable member of claim 2, wherein said antibiotic agents are selected from the group consisting of penicillins, cephalosporins, vancomycins, aminoglycosides, quinolones, polymyxins, erythromycins, tetracyclines, chloramphenicols, clindamycins, lincomycins, sulfonamides their homologs, analogs, derivatives, pharmaceutical salts and mixtures thereof.

5. The implantable member of claim 2, wherein said anti-tumor agents are selected from the group consisting of paclitaxel, docetaxel, alkylating agents including mechlorethamine, chlorambucil, cyclophosphamide, melphalan and ifosfamide;

antimetabolites including methotrexate, 6-mercaptopurine, 5-fluorouracil and cytarabine;

plant alkaloids including vinblastine, vincristine and etoposide;

antibiotics including doxorubicin, daunomycin, bleomycin, and mitomycin;

nitrosureas including carmustine and lomustine;

inorganic ions including cisplatin;

biological response modifiers including interferon;

angiostatin agents and endostatin agents;

enzymes including asparaginase; and

hormones including tamoxifen and flutamide their homologs, analogs, fragments, derivatives, pharmaceutical salts and mixtures thereof.

6. The implantable member of claim 2, wherein said anti-viral agents are selected from the group consisting of amantadines, rimantadines, ribavirins, idoxuridines, vidarabines, trifluridines, acyclovirs, ganciclovirs, zidovudines, foscarnets, interferons their homologs, analogs, fragments, derivatives, pharmaceutical salts and mixtures thereof.

7. The implantable member of claim 1, wherein said polymeric substrate is selected from the group consisting of polyurethanes, polycarbonates, polyethylenes, polypropylenes, polyvinyl chlorides, polyvinyl acetates, polystyrenes, polyureas, silicone rubbers, polyamides, polyaldehydes, natural rubbers, polyether-ester copolymers, styrene-butadiene copolymers, and combinations thereof.

8. The implantable member of claim 1, wherein said insoluble, biocompatible, biodegradable material includes gelatin.

9. The implantable member of claim 1, wherein said insoluble, biocompatible, biodegradable material includes extracellular matrix proteins.

10. The implantable member of claim 9, wherein said extracellular matrix proteins are selected from the group consisting of collagen, including collagen Type I, collagen Type II, collagen Type III, collagen Type IV, and collagen Type V, vitronectin, fibronectin, laminin, reconstituted basement membrane matrices, and derivatives and mixtures thereof.

11. The implantable member of claim 1, wherein a surface of said polymeric substrate is subjected to a silver ion-beam-assisted deposition process to render said substrate more antimicrobial.

12. The implantable member of claim 11, wherein silver is deposited onto said substrate via said ion-beam-assisted deposition process prior to filling said pores with said insoluble, biocompatible, biodegradable material.